Advanced

Once-daily fosamprenavir with ritonavir in the treatment of HIV infection in therapy-naïve patients.

Flamholc, Leo LU and Gisslén, Magnus (2008) In Therapeutics and Clinical Risk Management 4(6). p.1281-1284
Abstract
Treatment options for HIV patients have dramatically improved since the introduction of efficacious antiretroviral combination therapy more than a decade ago. Treatment regimens have been simplified with fewer pills and fewer daily dosages. Fosamprenavir is a protease inhibitor with a rather long half-life which makes it a candidate for once-daily use. Once-daily dosage of ritonavir-boosted fosamprenavir is approved in the US, but not in Europe, for treatment in patients without prior antiretroviral treatment. Here we review the background and rationale for once-daily dosage of ritonavir-boosted fosamprenavir. The rather limited studies that have been published so far indicate that fosamprenavir 1400 mg may be used once daily boosted with... (More)
Treatment options for HIV patients have dramatically improved since the introduction of efficacious antiretroviral combination therapy more than a decade ago. Treatment regimens have been simplified with fewer pills and fewer daily dosages. Fosamprenavir is a protease inhibitor with a rather long half-life which makes it a candidate for once-daily use. Once-daily dosage of ritonavir-boosted fosamprenavir is approved in the US, but not in Europe, for treatment in patients without prior antiretroviral treatment. Here we review the background and rationale for once-daily dosage of ritonavir-boosted fosamprenavir. The rather limited studies that have been published so far indicate that fosamprenavir 1400 mg may be used once daily boosted with ritonavir. The optimal ritonavir dose to be given together with fosamprenavir is still to be defined, though available results indicate that a dose of 100 mg may be adequate provided that no protease inhibitor resistance is present. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Therapeutics and Clinical Risk Management
volume
4
issue
6
pages
1281 - 1284
publisher
Dove Medical Press Ltd.
external identifiers
  • PMID:19337434
  • Scopus:61549109625
ISSN
1176-6336
language
English
LU publication?
yes
id
ae393ddf-706e-47e6-8f08-712064907f48 (old id 1392539)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/19337434?dopt=Abstract
date added to LUP
2009-05-04 15:46:56
date last changed
2016-10-13 04:34:08
@misc{ae393ddf-706e-47e6-8f08-712064907f48,
  abstract     = {Treatment options for HIV patients have dramatically improved since the introduction of efficacious antiretroviral combination therapy more than a decade ago. Treatment regimens have been simplified with fewer pills and fewer daily dosages. Fosamprenavir is a protease inhibitor with a rather long half-life which makes it a candidate for once-daily use. Once-daily dosage of ritonavir-boosted fosamprenavir is approved in the US, but not in Europe, for treatment in patients without prior antiretroviral treatment. Here we review the background and rationale for once-daily dosage of ritonavir-boosted fosamprenavir. The rather limited studies that have been published so far indicate that fosamprenavir 1400 mg may be used once daily boosted with ritonavir. The optimal ritonavir dose to be given together with fosamprenavir is still to be defined, though available results indicate that a dose of 100 mg may be adequate provided that no protease inhibitor resistance is present.},
  author       = {Flamholc, Leo and Gisslén, Magnus},
  issn         = {1176-6336},
  language     = {eng},
  number       = {6},
  pages        = {1281--1284},
  publisher    = {ARRAY(0x9ccd0f8)},
  series       = {Therapeutics and Clinical Risk Management},
  title        = {Once-daily fosamprenavir with ritonavir in the treatment of HIV infection in therapy-naïve patients.},
  volume       = {4},
  year         = {2008},
}